Basic Research
The
faculty at CVINJ has participated in the development and evaluation
of over one hundred cardiovascular agents and devices, including
beta blockers for heart failure, diuretics, ACE inhibitors for heart
failure and coronary heart disease, HMG CoA reductase inhibitors
for high-risk patients, nitrates, angiotensin-II receptor antagonists,
anti-arrhythmic agents, dual ACE-endopeptidase inhibitors, and endothelin
antagonists, among others. The use of statins and ACE inhibitors
has resulted in a 30% decrease in mortality in patients with cardiovascular
disease.
|
